Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].

Identifieur interne : 000114 ( Ncbi/Merge ); précédent : 000113; suivant : 000115

[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].

Auteurs : Tao Ren [République populaire de Chine] ; Ying-Yun Cai ; Yong-Jie Liang ; Mei-Ling Jin ; Zhong-Liang Guo ; Meng-Fei Tao ; Xiang He

Source :

RBID : pubmed:18844109

Descripteurs français

English descriptors

Abstract

To assess the modulation of TLR9 on anti-tumor immune responses in peripheral blood mononuclear cells (PBMC) from patients with non-small-cell lung cancer (NSCLC).

PubMed: 18844109

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:18844109

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].</title>
<author>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai 200120, China. rentao305@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai 200120</wicri:regionArea>
<wicri:noRegion>Shanghai 200120</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
</author>
<author>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
</author>
<author>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
</author>
<author>
<name sortKey="Guo, Zhong Liang" sort="Guo, Zhong Liang" uniqKey="Guo Z" first="Zhong-Liang" last="Guo">Zhong-Liang Guo</name>
</author>
<author>
<name sortKey="Tao, Meng Fei" sort="Tao, Meng Fei" uniqKey="Tao M" first="Meng-Fei" last="Tao">Meng-Fei Tao</name>
</author>
<author>
<name sortKey="He, Xiang" sort="He, Xiang" uniqKey="He X" first="Xiang" last="He">Xiang He</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18844109</idno>
<idno type="pmid">18844109</idno>
<idno type="wicri:Area/PubMed/Corpus">000413</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000413</idno>
<idno type="wicri:Area/PubMed/Curation">000413</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000413</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000400</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000400</idno>
<idno type="wicri:Area/Ncbi/Merge">000114</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].</title>
<author>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai 200120, China. rentao305@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai 200120</wicri:regionArea>
<wicri:noRegion>Shanghai 200120</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
</author>
<author>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
</author>
<author>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
</author>
<author>
<name sortKey="Guo, Zhong Liang" sort="Guo, Zhong Liang" uniqKey="Guo Z" first="Zhong-Liang" last="Guo">Zhong-Liang Guo</name>
</author>
<author>
<name sortKey="Tao, Meng Fei" sort="Tao, Meng Fei" uniqKey="Tao M" first="Meng-Fei" last="Tao">Meng-Fei Tao</name>
</author>
<author>
<name sortKey="He, Xiang" sort="He, Xiang" uniqKey="He X" first="Xiang" last="He">Xiang He</name>
</author>
</analytic>
<series>
<title level="j">Zhonghua yi xue za zhi</title>
<idno type="ISSN">0376-2491</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Antigens, CD (blood)</term>
<term>Antigens, Differentiation, T-Lymphocyte (blood)</term>
<term>CD3 Complex (blood)</term>
<term>Carcinoma, Non-Small-Cell Lung (blood)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Cell Line, Tumor</term>
<term>Cell Proliferation (drug effects)</term>
<term>Cells, Cultured</term>
<term>Chloroquine (pharmacology)</term>
<term>Female</term>
<term>Flow Cytometry</term>
<term>Humans</term>
<term>Interferon-alpha (blood)</term>
<term>Lectins, C-Type</term>
<term>Leukocytes, Mononuclear (cytology)</term>
<term>Leukocytes, Mononuclear (drug effects)</term>
<term>Leukocytes, Mononuclear (metabolism)</term>
<term>Lung Neoplasms (blood)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Oligodeoxyribonucleotides (genetics)</term>
<term>Oligodeoxyribonucleotides (pharmacology)</term>
<term>RNA, Messenger (genetics)</term>
<term>RNA, Messenger (metabolism)</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Toll-Like Receptor 9 (agonists)</term>
<term>Toll-Like Receptor 9 (genetics)</term>
<term>Toll-Like Receptor 9 (metabolism)</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>ARN messager (génétique)</term>
<term>ARN messager (métabolisme)</term>
<term>Adulte d'âge moyen</term>
<term>Agranulocytes ()</term>
<term>Agranulocytes (cytologie)</term>
<term>Agranulocytes (métabolisme)</term>
<term>Antigènes CD (sang)</term>
<term>Antigènes de différenciation des lymphocytes T (sang)</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (sang)</term>
<term>Cellules cancéreuses en culture</term>
<term>Cellules cultivées</term>
<term>Chloroquine (pharmacologie)</term>
<term>Cytométrie en flux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Interféron alpha (sang)</term>
<term>Lectines de type C</term>
<term>Lignée cellulaire tumorale</term>
<term>Mâle</term>
<term>Oligodésoxyribonucléotides (génétique)</term>
<term>Oligodésoxyribonucléotides (pharmacologie)</term>
<term>Prolifération cellulaire ()</term>
<term>RT-PCR</term>
<term>Récepteur-9 de type Toll-like (agonistes)</term>
<term>Récepteur-9 de type Toll-like (génétique)</term>
<term>Récepteur-9 de type Toll-like (métabolisme)</term>
<term>Sujet âgé</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (sang)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en">
<term>Toll-Like Receptor 9</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antigens, CD</term>
<term>Antigens, Differentiation, T-Lymphocyte</term>
<term>CD3 Complex</term>
<term>Interferon-alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="agonistes" xml:lang="fr">
<term>Récepteur-9 de type Toll-like</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr">
<term>Agranulocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cell Proliferation</term>
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Oligodeoxyribonucleotides</term>
<term>RNA, Messenger</term>
<term>Toll-Like Receptor 9</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>ARN messager</term>
<term>Oligodésoxyribonucléotides</term>
<term>Récepteur-9 de type Toll-like</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Leukocytes, Mononuclear</term>
<term>RNA, Messenger</term>
<term>Toll-Like Receptor 9</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>ARN messager</term>
<term>Agranulocytes</term>
<term>Récepteur-9 de type Toll-like</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Chloroquine</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Chloroquine</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Antigènes CD</term>
<term>Antigènes de différenciation des lymphocytes T</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Interféron alpha</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Cell Line, Tumor</term>
<term>Cells, Cultured</term>
<term>Female</term>
<term>Flow Cytometry</term>
<term>Humans</term>
<term>Lectins, C-Type</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte d'âge moyen</term>
<term>Agranulocytes</term>
<term>Cellules cancéreuses en culture</term>
<term>Cellules cultivées</term>
<term>Cytométrie en flux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lectines de type C</term>
<term>Lignée cellulaire tumorale</term>
<term>Mâle</term>
<term>Prolifération cellulaire</term>
<term>RT-PCR</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">To assess the modulation of TLR9 on anti-tumor immune responses in peripheral blood mononuclear cells (PBMC) from patients with non-small-cell lung cancer (NSCLC).</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18844109</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>03</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0376-2491</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>88</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2008</Year>
<Month>Apr</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>Zhonghua yi xue za zhi</Title>
<ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>1168-72</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the modulation of TLR9 on anti-tumor immune responses in peripheral blood mononuclear cells (PBMC) from patients with non-small-cell lung cancer (NSCLC).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">PBMCs were isolated from 36 NSCLC patients. Lung cancer cells were isolated from these patients and further enriched. PBMCs were cultured in RPMI-1640 medium (blank control group), and medium with cytosine guanine oligodeoxynucleotide (CpG ODN, an TLR9 agonist) or control ODN for 72 h; and then flow cytometry was used to examine the expression of CD69 antigen on the surface of CD3 cells, [3H]-thymidine incorporation method was used to examine the cell proliferation, and the IFN-alpha level in the supernatant was measured. Another PBMCs were cultured in medium with interleukin (IL)-1 and then CpG ODN, control ODN, and CpG ODN + chloroquine or inhibitory ODN were added respectively for 24-48 h. Then the IFN-alpha in the supernatant was measured. Subsets were assessed by flow cytometry and the expression of TLR9-mRNA in freshly isolated PBMC was detected by RT-PCR. The production of interferon (IFN)-alpha in the PBMCs was measured by ELISA. The proliferation of the PBMCs was determined by [3H]-thymidine incorporation. The PBMCs co-cultured with CpG ODN and autologous lung tumor cells treated with mitomycin C were used as effector cells, and K562 cells and autologous tumor cells were used as target cells flow cytometry was used to detect the capacity of PBMCs to kill autologous lung tumor cells and K562 cells. Meanwhile we investigated the intracellular expression of IFN-gamma and IL-4 in CD8+ T.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The expression level of TLR9 of the PBMCs from patients was not significantly different from that of the PBMCs from the healthy donors. The proportion of CD69 antigen expressing CD3+ T cells of the CpG ODN group was (39.5 +/- 8.9)%, significantly higher than those of the blank control group [(8.8 +/- 1.2)%, t = 40.30, P = 0.00] ands control ODN group [(10.6 +/- 1.0)%, t = 41.85, P = 0.00]. Examination with beta liquid scintillation counter showed that the cpm value of the CpG ODN group was (1.61 +/- 0.20) x 10(4), significantly higher than those of the blank control group [(0.27 +/- 0.14) x 10(4), t = 20.43, P = 0.00] and control ODN group [(0.34 +/- 0.13) x 10(4), t =20.20, P = 0.00]. Chloroquine and inhibitory ODN dose-dependently inhibited the IFN-alpha levels in the supernatant. The CD4 + T/CD8 + T of the CpG ODN group was (3.44 +/- 0.20), significantly higher than those of the control ODN group (1.73 +/- 0.27, t = 19.85, P = 0.00) and blank control group (1.69 +/- 0.13, t = 29.32, P = 0.00). The IFN-gamma positive CD8 + T cells of the CpG ODN group was (18.5 +/- 4.2)%, significantly higher than those of the control ODN group [(4.2 +/- 1.0)%, t = 24.12, P = 0.00] and blank control group [(3.1 +/- 1.2)%, t = 25.1, P = 0.00]. There was no significant differences in the proportion of IL-4 positive CD8 + T cells among different groups. When the E/T was 40:1 the killing capacity of PBMCs against the K562 cells was (19.5 +/- 1.0), significantly higher than those of the control ODN group (7.9 +/- 1.1, t = 19.9, P = 0.00) and blank control group (5.1 +/- 1.6, t = 21.9, P = 0.00), and the killing capacity of PBMCs against the autologous lung tumor cells was (29.8 +/- 2.1), significantly higher than those of the control ODN group (8.1 +/- 0.9, t = 36.9, P = 0.00) and blank control group (5.7 +/- 1.6, t = 35.7, P = 0.00).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TLR9 signal takes part in the immunomodulation of PBMCs. The activation of TLR9 results in enhanced anti-tumor response in the PBMCs against autologous lung cancer cells and K562 cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai 200120, China. rentao305@163.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cai</LastName>
<ForeName>Ying-Yun</ForeName>
<Initials>YY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Yong-Jie</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Mei-Ling</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Zhong-Liang</ForeName>
<Initials>ZL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tao</LastName>
<ForeName>Meng-Fei</ForeName>
<Initials>MF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
<NlmUniqueID>7511141</NlmUniqueID>
<ISSNLinking>0376-2491</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000945">Antigens, Differentiation, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017252">CD3 Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C055855">CD69 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051217">Toll-Like Receptor 9</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000945" MajorTopicYN="N">Antigens, Differentiation, T-Lymphocyte</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017252" MajorTopicYN="N">CD3 Complex</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D037181" MajorTopicYN="N">Lectins, C-Type</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051217" MajorTopicYN="N">Toll-Like Receptor 9</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>10</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>10</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18844109</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
<name sortKey="Guo, Zhong Liang" sort="Guo, Zhong Liang" uniqKey="Guo Z" first="Zhong-Liang" last="Guo">Zhong-Liang Guo</name>
<name sortKey="He, Xiang" sort="He, Xiang" uniqKey="He X" first="Xiang" last="He">Xiang He</name>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
<name sortKey="Tao, Meng Fei" sort="Tao, Meng Fei" uniqKey="Tao M" first="Meng-Fei" last="Tao">Meng-Fei Tao</name>
</noCountry>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000114 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000114 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:18844109
   |texte=   [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:18844109" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021